- Home
- SANA
as 07-26-2024 4:00pm EST
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
Upcoming Earnings Alert:
Get ready for potential market movements as Sana Biotechnology Inc. SANA prepares to release earnings report on 01 Aug 2024.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 1.3B | IPO Year: | 2021 |
| Target Price: | $11.67 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.75 - $12.00 | Next Earning Date: | 08-01-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Sana Biotechnology Inc. (SANA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yang Patrick Y | SANA | Director | Mar 8 '24 | Sell | $9.45 | 25,000 | $236,300.00 | 149,250 | SEC Form 4 |
| CRANDELL KEITH | SANA | 10% Owner | Feb 8 '24 | Buy | $5.50 | 727,272 | $3,999,996.00 | 12,446,022 | SEC Form 4 |
| CRANDELL KEITH | SANA | 10% Owner | Feb 8 '24 | Buy | $5.50 | 727,272 | $3,999,996.00 | 12,446,022 | SEC Form 4 |
| CRANDELL KEITH | SANA | 10% Owner | Feb 8 '24 | Buy | $5.50 | 363,637 | $2,000,003.50 | 10,667,387 | SEC Form 4 |
| ARCH Venture Fund X, L.P. | SANA | 10% Owner | Feb 8 '24 | Buy | $5.50 | 363,637 | $2,000,003.50 | 10,667,387 | SEC Form 4 |
| ARCH Venture Fund X, L.P. | SANA | 10% Owner | Feb 8 '24 | Buy | $5.50 | 727,272 | $3,999,996.00 | 12,446,022 | SEC Form 4 |
| ARCH Venture Fund X, L.P. | SANA | 10% Owner | Feb 8 '24 | Buy | $5.50 | 727,272 | $3,999,996.00 | 12,446,022 | SEC Form 4 |
| NELSEN ROBERT | SANA | Director10% Owner | Feb 8 '24 | Buy | $5.50 | 363,637 | $2,000,003.50 | 10,667,387 | SEC Form 4 |
| NELSEN ROBERT | SANA | Director10% Owner | Feb 8 '24 | Buy | $5.50 | 727,272 | $3,999,996.00 | 12,446,022 | SEC Form 4 |
| NELSEN ROBERT | SANA | Director10% Owner | Feb 8 '24 | Buy | $5.50 | 727,272 | $3,999,996.00 | 12,446,022 | SEC Form 4 |
| Hordo Christian | SANA | EVP, Chief Business Officer | Dec 15 '23 | Sell | $4.00 | 75,000 | $300,097.50 | 867,455 | SEC Form 4 |
Latest Sana Biotechnology Inc. News
SANA Breaking Stock News: Dive into SANA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
Simply Wall St.
3 months ago
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?
GuruFocus.com
3 months ago
Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results
Associated Press Finance
3 months ago
Sana: Q1 Earnings Snapshot
GlobeNewswire
3 months ago
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
3 months ago
Sana Biotechnology to Present at May and June 2024 Investor Conferences
Zacks
3 months ago
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
GuruFocus.com
5 months ago
Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)
Compare SANA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SANA Sana Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.